Replies to post #211022 on Biotech Values

[DewDiligence]

AZN withdraws Imfinzi in bladder cancer after failure to show survival advantage in post-marketing study:

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html

The FDA gave Imfinzi accelerated approval in bladder cancer (its first approved indication) in 2017, based on ORR/DoR data in a phase-2 trial (#msg-130966037).